Publication details
Studie RELAX-AHF2:RELAXin in Acute Heart Failure-2
| Title in English | The RELAX-AHF2 Trial:RELAXin in Acute Heart Failure-2 |
|---|---|
| Authors | |
| Year of publication | 2018 |
| Type | Article in Periodical |
| Magazine / Source | Intervenční a akutní kardiologie |
| MU Faculty or unit | |
| Citation | |
| Keywords | acute heart failure, serelaxin,cardiovascular mortality, overall mortality, safety |
| Description | Serelaxin is a recombinant form of human relaxin-2 with favourable haemodynamic properties.The RELAX AHF trial tested this substance in patients with acute heart failure. There was no improvement in 5 days hospitalisation and no reduction in 180 days cardiovascular mortality. There was no difference in all-cause mortality. The study was well tolerated with adverse effects comparable to placebo. |